Brought to you by 
Tesaro licenses exclusive rights to Merck's cancer therapy niraparib
29 Mar 2017
Executive Summary
Cancer drug start-up Tesaro Inc. has in-licensed its third development program, this time from Merck & Co. Inc. and its Merck Sharp & Dohme Ltd. division. Tesaro gets exclusive worldwide rights to develop, manufacture, and sell Merck’s Phase I niraparib and back-up compound MK2512.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tesaro licenses exclusive rights to Merck's cancer therapy niraparib
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice